Commercial success in a competitive market hinges on a sequence of hard questions. Where are patients underserved? What does our asset offer that others don't? Who do we go after first — and can they actually access the therapy? The use cases below are built around those questions.
Each one shows the prompt we'd actually run, a snippet of what Cheiron returns, and a link to the full grounded response with citations.
New to Cheiron? Start with Getting Started with Cheiron and How Cheiron Grounds Answers (Deep Citations) — they explain why every answer below is auditable back to it's source.
Compare Therapies
Example question:
”How do FDA-approved biologic therapies for moderate-to-severe plaque psoriasis differ in terms of patient experience, including administration, tolerability, and treatment burden?”
Cheiron’s response:
FDA-approved biologics for moderate-to-severe plaque psoriasis differ most in where treatment happens, how often patients must inject or attend visits, and how much “treatment friction” patients feel from needles, refrigeration/travel, lab or safety concerns, and fear of immunosuppression. Patient preferences are heterogeneous: some patients view injections as convenient...
Tip: Go beyond efficacy data — understand how approved therapies differ in administration, tolerability, and treatment burden from the patient’s perspective.
Assess Market Opportunities
Example question:
”Assess unmet needs in major depressive disorder despite recent antidepressant advances.”
Cheiron’s response:
Recent MDD advances—especially intranasal esketamine and dextromethorphan-bupropion—have improved the landscape by adding faster-acting, non-monoaminergic options, but they have not eliminated the core unmet needs: many patients still do not remit, durability remains a challenge, TRD carries high relapse/suicide/function burden, treatment selection is still...
Tip: Surface the gaps that existing therapies leave behind — and translate them into clearly defined commercial opportunities.
Sharpen Product Positioning
Example question:
”How should a new oral JAK inhibitor position its value proposition to differentiate from existing treatments in moderate-to-severe ulcerative colitis?”
Cheiron’s response:
A new oral JAK inhibitor should not position itself as “another convenient oral option.” The strongest differentiated value proposition would be: Rapid, deep, steroid-sparing disease control for high-need moderate-to-severe UC patients, especially biologic- or TNF-exposed patients, with a safety and monitoring profile designed to improve on current JAK trade-offs. This positioning fits...
Tip: Define what makes your asset worth choosing — and how to articulate that to a market that already has options.
Develop Launch Strategy
Example question:
”What target patient segments should be prioritized at launch for a new biologic entering the moderate-to-severe Crohn's disease market?”
Cheiron’s response:
Prioritize the launch around advanced-therapy–exposed Crohn’s disease patients first, then expand into biologic-naïve moderate luminal patients where safety, tolerability, or convenience can differentiate; be cautious in perianal/fistulizing, stricturing, postoperative, and isolated small-bowel segments unless...
Tip: Determine which patient populations represent the strongest fit at launch — and why prioritizing them creates the right commercial foundation.
Pressure-Test Pricing & Market Access
Example question:
"What are the key market access barriers for a high-cost biologic in Japan, Germany, and the UK?”
Cheiron’s response:
For a high-cost biologic, the main barriers differ by market: Japan is mainly a post-launch price-adjustment and ICER risk market, Germany is an added-benefit versus comparator and negotiated net-price market, and the UK is a NICE cost-effectiveness, affordability, and commercial-agreement market. Japan and Germany generally preserve initial reimbursement or...
Tip: Map the reimbursement and access hurdles your therapy will face — before they become launch obstacles.
These examples are only a starting point. To explore additional questions, see Ask Cheiron for guidance on writing questions and reviewing answers.